Recent Updates
Recently added Catalysts

BMS-986470

Phase 1

Anemia, Sickle Cell | Small molecule | Hematology |Bristol-Myers Squibb Company|Last Updated: Jul 6, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment224
FDA Designations
No designations recorded
Clinical trial landscape

BMS-986470 · 1 trial · 2 indications

Phase 1 1
NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseAnemia, Sickle Cell
RECRUITING224 Analytics
PHASE1RECRUITING
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Anemia, Sickle Cell
NCT06481306224
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of participants with adverse events (AEs)
Up to 26 months
Number of participants with serious adverse events (SAEs)
Up to 26 months
Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria
Up to 26 months
Number of participants with AEs leading to discontinuation
Up to 26 months
Number of deaths
Up to 26 months
Proportion of participants achieving HbF ≥ 10%
Up to 28 days after last dose
Proportion of participants achieving HbF ≥ 20%
Up to 28 days after last dose
Proportion of participants achieving HbF ≥ 30%
Up to 28 days after last dose
Secondary Endpoints
Maximum observed plasma concentration (Cmax)
Up to Day 28
Area under the concentration-time curve (AUC)
Up to Day 28
Time of maximum observed plasma concentration (Tmax)
Up to Day 28
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort A Part 1EXPERIMENTAL -
Cohort A Part 2EXPERIMENTAL -
Cohort A Part 3EXPERIMENTAL -
Cohort B Part 1EXPERIMENTAL -
Cohort B Part 2EXPERIMENTAL -
Interventions
NameTypeDescription
BMS-986470DRUGSpecified dose on specified days
PlaceboDRUGSpecified dose on specified days
FamotidineDRUGSpecified dose on specified days
PantoprazoleDRUGSpecified dose on specified days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites33

Inclusion Criteria: Cohort A: * Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alt...

Countries:United StatesCanadaFranceItalyUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMJul 6, 2026NCT06481306Enrollment: 184 → 224
MEDIUMJul 6, 2026NCT06481306Enrollment: 184 → 224
LOWJun 16, 2026NCT06481306lastUpdatePostDate: changed
LOWJun 16, 2026NCT06481306lastUpdatePostDate: changed
LOWJun 16, 2026NCT06481306lastUpdatePostDate: changed
LOWMay 26, 2026NCT06481306primaryCompletionDate: changed
LOWMay 24, 2026NCT06481306studyFirstPostDate: changed